Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa. …
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Patients move to reclaim access agenda ahead of sector negotiations
July 15, 2026 - - Latest News -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News -
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 - - Latest News -
An opportunity to become a global destination for paediatric oncology trials
July 15, 2026 - - Latest News -
Widening inequality threatens outcomes for Australians with neuroendocrine cancer
July 14, 2026 - - Latest News -
Can GLP-1s be more transformative than AI - one person believes they already are
July 14, 2026 - - Latest News